Artivion granted fda humanitarian device exemption for the amds hybrid prosthesis

Atlanta , dec. 9, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the u.s. food and drug administration (fda) has granted a humanitarian device exemption (hde) for use of the amds hybrid prosthesis ("amds") in acute debakey type i dissections in the presence of malperfusion. the amds is the world's first aortic arch remodeling device for use in the treatment of acute debakey type i aortic dissections.
AORT Ratings Summary
AORT Quant Ranking